Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Vincerx Pharma Inc (OQ:VINC)

Business Focus: Bio Therapeutic Drugs

INK Edge Outlook

Mostly sunny as of April 01, 2024
For the latest outlook, get the company report

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEC Form 4 filings for VINC*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Apr 26, 2024 00:27 ET
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock, and...
Read full article
Apr 25, 2024 16:01 ET
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.09
--
--
Price to Sales - TTM
--
6.00
3.16
Price to Book - most recent quarter
1.60
2.13
2.08
Price to Cash Flow per share - TTM
--
17.52
13.71
Price to Free Cash Flow per share - TTM
--
19.54
23.72
See all valuations

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.

See business summary

 

Twitter

Search (past week) for $VINC

  • No tweets found